HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

PHASE3CompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

October 1, 2016

Primary Completion Date

November 28, 2020

Study Completion Date

November 28, 2020

Conditions
HepatoCellular Carcinoma
Interventions
PROCEDURE

Hepatic arterial infusion chemotherapy

A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially.

PROCEDURE

Transarterial chemoembolization

Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.

DRUG

Folfox Protocol

oxaliplatin,leucovorin and 5-FU

DRUG

TACE Drug Protocol

lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, with or without MMC) followed by polyvinyl alcohol particles (PVA)

Trial Locations (3)

510060

The First People's Hospital of Foshan, Foshan

Cancer Center Sun Yat-sen University, Guangzhou

510620

Guangzhou Twelfth People's Hospital, Guangzhou

All Listed Sponsors
collaborator

Guangzhou No.12 People's Hospital

OTHER_GOV

collaborator

First People's Hospital of Foshan

OTHER

lead

Sun Yat-sen University

OTHER

NCT02973685 - HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B. | Biotech Hunter | Biotech Hunter